Neuro-immune-endocrine mechanisms with poor adherence to aromatase inhibitor therapy in breast cancer

As the most commonly used endocrine therapy regimen for patients with hormone receptor-positive (HR+) breast cancer (BC) at present, aromatase inhibitors (AIs) reduce the risk of localized and distant recurrence, contralateral BC and secondary cancer, and prolong disease-free survival. Clinical data...

Descripción completa

Detalles Bibliográficos
Autores principales: Huifang, Li, Jie, Gao, Yi, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791186/
https://www.ncbi.nlm.nih.gov/pubmed/36578931
http://dx.doi.org/10.3389/fonc.2022.1054086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791186/
https://www.ncbi.nlm.nih.gov/pubmed/36578931
http://dx.doi.org/10.3389/fonc.2022.1054086

Ejemplares similares